As far as we know, interplanetary travel could take up to years, with the journey to Mars alone taking almost a year to make. As NASA prepares for its upcoming Mars and Moon missions, the agency has received a promising design for a spacecraft engine that could potentially speed up space travel by a big amount.
The design was drafted by Seattle, Washington-based company Ultra Safe Nuclear Technologies, which details the use of a nuclear thermal propulsion engine. The firm designed the NTP with the Mars mission in mind, the NTP being able to take humans from Earth to Mars in a span of only three months. Their design follows NASA’s plans to venture into the use of nuclear power for its future space missions.
A nuclear thermal propulsion engine system makes use of nuclear fission or power from splitting atoms to create thrust. This is typically the more efficient method compared to chemical rockets that are more commonly used.
“We want to lead the effort to open new frontiers in space and do it quickly and safely,” said USNC-Tech principal engineer Michael Eades. Eades also noted that their design would be more reliable than other designs and that it also has a specific impulse or amount of thrust from a propellant that is more than two times the amount of chemical systems.
With this method, experts believe that it could reduce the travel time from Earth to Mars one way by a significant amount. Using an NTP would only take three months from Earth to Mars in one way.
Aside from the upcoming Mars and Moon missions, there is also the ongoing probe into the asteroid Bennu being done by NASA. The agency released photos showing the landing of the Osiris-REx spacecraft onto the asteroid, and images of the spacecraft collecting soil samples. This is NASA’s first try in collecting asteroid samples a year after Japan’s own space agency JAXA bombed another asteroid, Ryugu, to collect samples.
The samples from Bennu would be returning to Earth by 2023, and the samples from Ryugu would be returning by the end of 2020.


NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Neuralink Expands Brain Implant Trials with 12 Global Patients
Tabletop particle accelerator could transform medicine and materials science
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 



